Predicting Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score-Pathology-Clinical (RSPC) Tool
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVE

- Recognize the strengths and weaknesses of the novel RSPC relative to the standard Oncotype DX RS as a prognostic and/or predictive breast cancer biomarker.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Paid Research: Merck and Company Inc, Onyx Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium, The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: February 2011
Expiration date: February 2012
Click here for key papers on genomic predictors from the 2010 SABCS

Last Friday, our CME group welcomed seven winter-weary breast cancer investigators to the RTP recording studio in sunny Miami, this time for our annual post-SABCS Think Tank. As usual, the best part of the day was when these learned souls presented challenging cases from their practices and asked each other what they would do for the patients discussed.

Probably the least frozen faculty member was Northern Californian Hope Rugo, who put the group on its heels with a challenging situation: A 47-year-old highly informed premenopausal woman seeking another opinion about a recently removed 0.8-cm, Grade I, ER-positive, HER2-negative invasive ductal cancer in which one sentinel node had a 0.9-cm focus of tumor. Ki-67 obtained at the referring community hospital was less than five percent.

“Would you order an Oncotype DX® on this lady?” was Hope’s question, and the answers were quite interesting. Two investigators said no to Oncotype and suggested TC followed by hormones. Harold Burstein represented most of the others believing an Oncotype would add useful information, particularly when Hope noted that this woman was willing to receive chemo but was not insistent on it. Some of the group had been sipping home-brewed Cuban coffee, which may partially explain the heated discussions on this and other topics (keep an eye open for the upcoming audio highlight program), but all wished to hear the follow-up from Hope about what actually happened.

Dr Rugo related that the patient had actually consulted with two prior oncologists, the first of whom had recommended TC straight up (to be followed by hormones) while the second had recommended hormone therapy only. Dr Rugo decided to obtain an Oncotype, which returned a Recurrence Score® of 0 (that’s low!). The patient has been contentedly taking tamoxifen for two years.
As part of the discussion surrounding the case, Antonio Wolff noted that now a good option for a woman in this situation would be entry into the upcoming SWOG/Intergroup RESPOND trial, randomly assigning patients with ER-positive, HER2-negative tumors, one to three positive nodes and a Recurrence Score of 25 or less to endocrine therapy alone or preceded by chemo. Of course, until that study is complete, we will have to rely on other accumulating evidence in the field, including the following papers presented at San Antonio:

1. **Another data set** (following one at ASCO 2010) from the NSABP on the RSPC — Recurrence Score-Pathology-Clinical risk assessment

   According to Chuck Geyer, seven years after Soon Paik’s presentation (at San Antonio) of the first Oncotype DX/NSABP analysis, the group still is attempting to fulfill the mission of the late statistician and group linchpin John Bryant and figure out how to integrate clinical factors in addition to Oncotype into treatment decisions. It is easy to understand the interest in having more information on patients like Hope’s, for whom there is a disconnect between the clinical factors predicting the risk of recurrence (small, low-grade, low Ki67 but node-positive). The RSPC calculation uses commonly available variables like tumor size and grade but unfortunately doesn’t seem to add much to the Recurrence Score in terms of what’s most important — prediction of benefit from chemo.

2. **A Meta-analysis** of seven studies (n = 912) evaluating the impact of Oncotype DX on clinical decision-making

   Our CME group’s national *Patterns of Care studies* have demonstrated that when utilized, Oncotype changes the clinical decision made in at least a quarter of cases and in this meta-analysis, decisions were changed for 37 percent of patients with a 28 percent overall decrease in the use of chemotherapy.

3. **A translational study** from Dana-Farber evaluating pre- and postneoadjuvant chemotherapy Recurrence Scores

   This fascinating report revealed that Recurrence Scores evaluated before and after neoadjuvant chemotherapy did not change substantially and continued to predict outcome, suggesting that treatment did not impact the tumor’s genomic profile. Also of interest was a six to 11 percent discordance in ER/PR results with IHC versus RT-PCR.

   I first met Soon Paik (for an interview) in San Antonio the night before his classic 2003 presentation of the first Oncotype data set that set the stage for a new era in breast cancer and oncology, emphasizing a biologic approach to the development of new
treatments and predictors of response. Seven years later, as evidenced by his Brinker Award lecture (the last of the Thursday lectures), Dr Paik continues to have a vision for the future of clinical research that is far ahead of the rest of us.

Next up on 5-Minute Journal Club: Endocrine treatment, pregnancy, obesity and breast cancer.

Neil Love, MD
Research To Practice
Miami, FL
Predicting Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score-Pathology-Clinical (RSPC) Tool

Presentation discussed in this issue

Tang G et al.Comparing the prediction of treatment benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score. San Antonio Breast Cancer Symposium 2010;Abstract S4-9.

Slides from a presentation at SABCS 2010 and comments from Clifford Hudis, MD at an RTP satellite symposium during SABCS 2010 (12/11/10)

Comparing the Prediction of Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score

Tang G et al.
Proc SABCS 2010;Abstract S4-9.
Objective

- To compare the value of a new clinical tool called the Recurrence Score-Pathology-Clinical (RSPC) risk assessment vs the Oncotype DX® Recurrence Score® (RS) in predicting chemotherapy benefit.
  - The RSPC was developed to assess risk of distant recurrence by integrating:
    - RS
    - Tumor grade
    - Pathologic tumor size
    - Patient age at surgery
    - Hormonal therapy (tamoxifen or anastrozole)


Methods

- Retrospective analysis of data from the NSABP-B-20 trial
- Eligibility
  - Participated in the NSABP-B-20 trial (ie, node-negative, ER-positive) of tamoxifen (TAM) or TAM plus chemotherapy (TAM/chemo).
  - Successful Oncotype DX RS
  - ER score ≥6.5
- The chemotherapy benefit associated with each risk assessment tool was determined using a Cox proportional hazards regression model to determine RS or RSPC risk benefit x treatment interaction.

## Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>TAM alone</th>
<th>TAM/chemo</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinically eligible with evaluable tumor block, n</td>
<td>227</td>
<td>424</td>
<td>651</td>
</tr>
<tr>
<td>Oncotype DX and ER ≥6.5, n (%)</td>
<td>225 (99.1%)</td>
<td>400 (94.3%)</td>
<td>625 (96%)</td>
</tr>
<tr>
<td>Distant recurrence events, n</td>
<td>31</td>
<td>29</td>
<td>60</td>
</tr>
</tbody>
</table>


## Patient Characteristics by Treatment Group (N = 625)

<table>
<thead>
<tr>
<th></th>
<th>TAM alone</th>
<th>TAM/chemo</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS, mean</td>
<td>20</td>
<td>21</td>
</tr>
<tr>
<td>Tumor grade*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>25%</td>
<td>24%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>41%</td>
<td>51%</td>
</tr>
<tr>
<td>High</td>
<td>34%</td>
<td>25%</td>
</tr>
<tr>
<td>Tumor size, mean</td>
<td>2.1 cm</td>
<td>2.1 cm</td>
</tr>
<tr>
<td>Age at surgery, mean</td>
<td>52 years</td>
<td>52 years</td>
</tr>
<tr>
<td>RSPC, mean</td>
<td>-2.05</td>
<td>-2.05</td>
</tr>
</tbody>
</table>

*p = 0.037 for TAM vs TAM/chemo*

### Prediction of Chemotherapy Benefit

<table>
<thead>
<tr>
<th></th>
<th>Hazard ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS*</td>
<td>2.22 (1.75-2.82)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment</td>
<td>0.63 (0.35-1.11)</td>
<td>0.11</td>
</tr>
<tr>
<td>RS* x treatment</td>
<td>0.65 (0.44-0.97)</td>
<td>0.034</td>
</tr>
<tr>
<td>RSPC*</td>
<td>2.43 (1.68-3.54)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment</td>
<td>0.64 (0.35-1.18)</td>
<td>0.156</td>
</tr>
<tr>
<td>RSPC* x treatment</td>
<td>0.65 (0.39-1.09)</td>
<td>0.1</td>
</tr>
</tbody>
</table>

*Standardized with standard deviation = 1.


---

### Prediction of Chemotherapy Benefit by Risk Group

<table>
<thead>
<tr>
<th></th>
<th>TAM alone</th>
<th>TAM+ chemo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Included B-20 Patients</td>
<td>225</td>
<td>400</td>
</tr>
<tr>
<td><strong>RS Risk Groups</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>135</td>
<td>217</td>
</tr>
<tr>
<td>Intermediate</td>
<td>45</td>
<td>90</td>
</tr>
<tr>
<td>High</td>
<td>45</td>
<td>93</td>
</tr>
<tr>
<td><strong>RSPC Risk Groups</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>116</td>
<td>216</td>
</tr>
<tr>
<td>Intermediate</td>
<td>48</td>
<td>71</td>
</tr>
<tr>
<td>High</td>
<td>61</td>
<td>113</td>
</tr>
</tbody>
</table>

**Interaction:** p = 0.022

**Interaction:** p = 0.15

With permission from Tang G et al. *Proc SABCS* 2010;Abstract S4-9.
Conclusions

- The prediction of chemotherapy benefit was not improved with RSPC compared with RS.
  - Treatment interaction for RS x chemotherapy treatment was significant ($p = 0.034$) compared with that of RSPC ($p = 0.10$).
- The recommended method to predict chemotherapy benefit is RS alone.


Investigator Commentary: Prediction of Chemotherapy Benefit with the Recurrence Score with or without Clinical and Pathologic Factors

I believe the Recurrence Score-Pathology-Clinical (RSPC) risk assessment approach undermines the value of the Oncotype DX assay, which is a gene-based assessment of chemotherapy sensitivity. In this study the investigators added in clinical and pathologic factors — with which, in multivariate analyses performed in the early days, the Recurrence Score was demonstrated to be superior.

The RSPC increased the number of patients who are deemed to have “low-risk” disease, but we lose the distinguishing feature of the Oncotype DX assay, which is its ability to predict chemotherapy benefit. The predictive utility is key for me because it’s always been what distinguished the Oncotype DX assay from many other available prognostic tests. So, at the moment, it’s difficult to see what advantage the RSPC offers compared to other prognostic tests. Currently, the Oncotype DX assay is the only test that has any degree of validation for prediction of benefit from chemotherapy, and that goes away under this RSPC model.

Commentary by Clifford Hudis, MD, December 11, 2010